Grown Rogue International (GRUSF) Common Equity (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly Common Equity came in at $16.8 million in Q1 2026, up 10.44% year-on-year from $15.2 million in Q1 2025, and down 29.6% quarter-over-quarter from $23.9 million in Q4 2025.
Grown Rogue International (GRUSF) Common Equity (2009 - 2026) Analysis & Trends
Grown Rogue International's Common Equity history runs 18 years deep, the most recent figure standing at $16.8 million for Q1 2026.
- On a quarterly basis, Common Equity rose 10.44% year-over-year to $16.8 million in Q1 2026; TTM through Mar 2026 was $16.8 million, a 10.44% increase from a year earlier, with the FY2025 full-year figure at $23.9 million, up 126.16% from the prior year.
- Common Equity fell to $16.8 million in Q1 2026 per GRUSF's latest filing, from $23.9 million in the prior quarter.
- Across five years, Common Equity topped out at $32239.6 billion in Q3 2025 and bottomed at $8.4 million in Q2 2024.
- The 5-year median for Common Equity is $11.1 million (2023), against an average of $2302.8 billion.
- Biggest YoY gain for Common Equity was 340581371.32% in 2025; the steepest drop was 0.72% in 2025.
- Year by year, Common Equity stood at $8.9 million in 2022, then climbed by 9.54% to $9.8 million in 2023, then advanced by 8.0% to $10.6 million in 2024, then soared by 126.16% to $23.9 million in 2025, then slipped by 29.6% to $16.8 million in 2026.
- Per Business Quant, the three latest GRUSF Common Equity figures stand at $16.8 million (Q1 2026), $23.9 million (Q4 2025), and $32239.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 16.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.84 Mn |
| Dec 31, 2025 | 23.92 Mn |
| Sep 30, 2025 | 32,239.64 Bn |
| Jun 30, 2025 | 28.89 Mn |
| Mar 31, 2025 | 15.25 Mn |
| Dec 31, 2024 | 10.58 Mn |
| Sep 30, 2024 | 9.47 Mn |
| Jun 30, 2024 | 8.39 Mn |
| Mar 31, 2024 | 15.36 Mn |
| Dec 31, 2023 | 9.79 Mn |
| Oct 31, 2023 | 11.56 Mn |
| Apr 30, 2023 | 10.09 Mn |
| Jan 31, 2023 | 9.59 Mn |
| Oct 31, 2022 | 8.94 Mn |
| Oct 31, 2021 | 7.12 Mn |
| Apr 30, 2021 | 4.93 Mn |
| Jan 31, 2021 | -1.56 Mn |
| Oct 31, 2020 | -945,019.00 |
| Jul 31, 2020 | 673,205.00 |
| Apr 30, 2020 | 14.18 Mn |